Plasminogen activators and their inhibitors in normal, hyperplastic and carcinomatous human endometrium. 1986

T Soszka, and K Olszewski

Plasminogen activators (PA) and inhibitors of urokinase were determined by a solid phase 125I-fibrin assay in endometrial tissue homogenates from 87 patients. PA was also determined by a histochemical method. Patients were divided according to histopathological diagnosis into three groups; normal, hyperplastic and cancerous. The mean values and S.D. of PA in control endometria, in hyperplastic endometria and in endometrial cancer were 0.68 +/- 0.55 units per mg protein, 1.9 +/- 1.6 units per mg protein and 3.21 +/- 1.03 units per mg protein, respectively. The results of the histochemical assay of PA correlated with the results of 125I-fibrin assay (R = 0.818, p less than or equal to 0.001). The relative PA activity of urokinase-type was the lowest in normal endometrium; it increased in hyperplastic and it was the highest in carcinomatous endometrium. The urokinase inhibitor activity was similar in control and carcinomatous groups; it was slightly but significantly higher in hyperplasia. The results support the contention that PA reflects malignant transformation of endometrial cells. We suggest that determination of PA may facilitate diagnosis and proper treatment of precancerous and cancerous states of endometrium.

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

T Soszka, and K Olszewski
January 1988, Methods in enzymology,
T Soszka, and K Olszewski
January 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
T Soszka, and K Olszewski
January 1991, Virchows Archiv. B, Cell pathology including molecular pathology,
T Soszka, and K Olszewski
October 1992, Sheng li xue bao : [Acta physiologica Sinica],
T Soszka, and K Olszewski
December 1992, Annals of the New York Academy of Sciences,
T Soszka, and K Olszewski
February 2006, European journal of oral sciences,
T Soszka, and K Olszewski
January 1995, Fertility and sterility,
Copied contents to your clipboard!